Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.85 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | APEX1 | P27695 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | NAMPT | P43490 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17194791 | 0.92 | SMN1; SMN2 (1.00) | SMN1; SMN2NR1H4RECQLHSD17B10LMNA | |
| SCHEMBL5681720 | 0.89 | ERCC1 (0.69) | SMN1; SMN2 | |
| SCHEMBL30646461 | 0.89 | ERCC1 (0.69) | SMN1; SMN2NR1H4L3MBTL1 | |
| SCHEMBL12172992 | 0.89 | SMN1; SMN2 (0.68) | SMN1; SMN2NR1H4LMNAROCK2L3MBTL1 | |
| SCHEMBL30613373 | 0.87 | SMN1; SMN2 (0.67) | SMN1; SMN2NR1H4ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL29356619 | 0.86 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1NAMPT | |
| SCHEMBL6270935 | 0.86 | ALDH1A1 (0.77) | SMN1; SMN2ALDH1A1NAMPT | |
| SCHEMBL28859140 | 0.85 | NR1H4 (0.82) | SMN1; SMN2NR1H4ALDH1A1LMNAROCK2 | |
| SCHEMBL12697047 | 0.85 | SMN1; SMN2 (0.64) | SMN1; SMN2NR1H4LMNAL3MBTL1 | |
| SCHEMBL6848908 | 0.85 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1LMNAL3MBTL1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1633714-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | claimed |
| WO-2004108675-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | claimed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8530506-B2 | Process for production of biphenyl derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-09-10 | — | — | US | disclosed |
| EP-2502919-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-09-13 | — | — | US | disclosed |
| EP-2417130-A2 | QUINAZOLINEDIONE DERIVATIVES, PREPARATION THEREOF AND VARIOUS THERAPEUTIC USES THEREOF | SANOFI (FR) | 2012-02-15 | — | — | EP | disclosed |
| WO-2011061996-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | 田辺三菱製薬株式会社 (JP) | 2011-05-26 | — | — | WO | disclosed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
| EP-1633714-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | Pfizer Limited (GB) | 2006-03-15 | — | — | EP | disclosed |
| WO-2004108675-A1 | 2-AMINO-PYRIDINE DERIVATIVES AS BETA-2 ADRENORECEPTOR AGONISTS | PFIZER LIMITED (GB) | 2004-12-16 | — | — | WO | disclosed |
| WO-2001030745-A1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-03 | — | — | WO | disclosed |
| EP-0548217-B1 | PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES | BUCHARDT OLE (DK) | 1997-04-09 | — | — | EP | disclosed |
| US-5580751-A | REACTING A PEPTIDE WITH A NUCLEOPHILIC AMINE IN THE PRESENCE OF TRYPSIN OR A CARBOXYPEPIDASE; NONENZYMATICALLY CLEAVING TO FORM THE PRODUCT | CARLSBERG A/S (DK) | 1996-12-03 | — | — | US | disclosed |
| EP-0548217-A1 | PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES. | BUCHARDT OLE (DK) | 1993-06-30 | — | — | EP | disclosed |
| WO-1992005271-A1 | PROCESS FOR THE PREPARATION OF C-TERMINALLY AMIDATED PEPTIDES | BUCHARDT OLE (DK) | 1992-04-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232283-A1 | PROCESS FOR PRODUCTION OF BIPHENYL DERIVATIVE | AGTR2, AGTR1, ACE | SMN1; SMN2 4872/4885NR1H4 130/4885ALDH1A1 906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.